1. Home
  2. SION vs JFIN Comparison

SION vs JFIN Comparison

Compare SION & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SION
  • JFIN
  • Stock Information
  • Founded
  • SION 2019
  • JFIN 2011
  • Country
  • SION United States
  • JFIN China
  • Employees
  • SION N/A
  • JFIN N/A
  • Industry
  • SION
  • JFIN Finance: Consumer Services
  • Sector
  • SION
  • JFIN Finance
  • Exchange
  • SION NYSE
  • JFIN Nasdaq
  • Market Cap
  • SION 920.2M
  • JFIN 969.7M
  • IPO Year
  • SION 2025
  • JFIN 2019
  • Fundamental
  • Price
  • SION $20.47
  • JFIN $17.99
  • Analyst Decision
  • SION Strong Buy
  • JFIN
  • Analyst Count
  • SION 1
  • JFIN 0
  • Target Price
  • SION $32.00
  • JFIN N/A
  • AVG Volume (30 Days)
  • SION 260.6K
  • JFIN 134.5K
  • Earning Date
  • SION 08-25-2025
  • JFIN 08-26-2025
  • Dividend Yield
  • SION N/A
  • JFIN 4.45%
  • EPS Growth
  • SION N/A
  • JFIN 2.88
  • EPS
  • SION N/A
  • JFIN 3.43
  • Revenue
  • SION N/A
  • JFIN $840,800,386.00
  • Revenue This Year
  • SION N/A
  • JFIN N/A
  • Revenue Next Year
  • SION N/A
  • JFIN N/A
  • P/E Ratio
  • SION N/A
  • JFIN $5.36
  • Revenue Growth
  • SION N/A
  • JFIN 4.83
  • 52 Week Low
  • SION $7.26
  • JFIN $4.00
  • 52 Week High
  • SION $25.19
  • JFIN $19.23
  • Technical
  • Relative Strength Index (RSI)
  • SION N/A
  • JFIN 60.92
  • Support Level
  • SION N/A
  • JFIN $17.86
  • Resistance Level
  • SION N/A
  • JFIN $18.70
  • Average True Range (ATR)
  • SION 0.00
  • JFIN 0.74
  • MACD
  • SION 0.00
  • JFIN 0.03
  • Stochastic Oscillator
  • SION 0.00
  • JFIN 83.09

About SION SIONNA THERAPEUTICS INC

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

Share on Social Networks: